Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase 2b, Multicentre, Randomised, Active-Controlled, Double Blind, Double Dummy, Parallel Group Study

NCT01344954 is registered in ClinicalTrials.gov with ThromboGenics as lead sponsor.

NCT NCT01344954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase 2b, Multicentre, Randomised, Active-Controlled, Double Blind, Double Dummy, Parallel Group Study
Lead sponsor
ThromboGenics
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
May 31, 2012
Enrollment
632 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis of venous thromboembolic events